These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11366521)

  • 1. What they say about non-nucleoside drugs.
    Posit Aware; 1999; 10(1):35-7. PubMed ID: 11366521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What they say about: non-nucleoside drugs.
    Posit Aware; 2000; 11(1):44-7. PubMed ID: 11366350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What they say about nucleoside drugs.
    Posit Aware; 1999; 10(1):28-34. PubMed ID: 11366520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 9. The non-nukes. Sustiva. Viramune. The two major players.
    Lee J
    Posit Aware; 2005; Spec No():12-5. PubMed ID: 15828103
    [No Abstract]   [Full Text] [Related]  

  • 10. Efavirenz: resistance and cross-resistance.
    Clotet B
    Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What they say about nucleotide drugs.
    Posit Aware; 1999; 10(1):44. PubMed ID: 11366523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
    Harris M; Montaner JS
    Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Viramune = Sustiva?
    Vázquez E
    Posit Aware; 2003; 14(3):23, 37. PubMed ID: 12866487
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded access programs.
    Treat Rev; 1997 Nov; (No 26-27):12. PubMed ID: 11364931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMP 266 trials recruiting, many cities -- protease inhibitor naive.
    James JS
    AIDS Treat News; 1997 Sep; (No 278):5-6. PubMed ID: 11364623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 19. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    Moreno S; Casado JL; Pérez-Elías MJ; Dronda F; Antela A; Moreno A; Gutiérrez C
    AIDS; 2003 Jun; 17(9):1413-4. PubMed ID: 12799573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.